This finding support the notion that BRCA associated cancers respond to PARP1 inhibitors due to abnormal HR and indicate this therapy as a possible treatment for all of the tumors displaying features of “BRCAness.” Olaparib was the first PARP1 inhibitor to be approved by the US FDA for the treatment of ovarian cancers with BRCA mutations but many others (e.g., Iniparib, Rucaparib, Niraparib, Veliparib, and BMN-673) are currently assessed in clinical trials, alone or in combination with either chemo or radiotherapy, for several “non-BRCA” tumors (Tangutoori et al., 2015). Here, PARP1 is linked to ovarian carcinoma.